Actionable news
All posts from Actionable news
Actionable news in ETRM: EnteroMedics Inc.,

ETRM Gets Recharged, NBY Awaits Dec Data, Will TXMD Rejoice This Qtr?

( - EnteroMedics Inc.'s (

) two year follow up results from a pivotal study of vBloc Neurometabolic Therapy for the treatment of obesity, dubbed ReCharge, has demonstrated clinically significant weight loss and sustained improvements in obesity related risk factors.

At 2 years, the average weight loss was 21% ± 25% excess weight loss or 8% ±10% total body weight loss (TBL). Fifty-eight percent of subjects had at least 5% TBL and 45% had at least 7.5% TBL. Only one serious complication has occurred in the 2 years, noted the company.

ETRM closed Wednesday's trading at $0.29, down 2.85%. In after hours, the stock was up 8.62% at $0.31.

NovaBay Pharmaceuticals Inc. (

) is expected to report results from a phase 2b trial evaluating its proprietary anti-microbial compound Auriclosene (NVC-422) to reduce urinary catheter blockage and encrustation in patients with long-term indwelling urinary catheters in early...